Navigation Links
Prostate Cancer Patient First in Spain to Receive Fast and Precise RapidArc(R) Radiotherapy Treatment from Varian
Date:6/1/2010

BARCELONA, Spain, June 1 /PRNewswire-FirstCall/ -- Clinicians at Institut Catala d'Oncologia (ICO) in Barcelona have carried out the first treatment in Spain using RapidArc® radiotherapy from Varian Medical Systems (NYSE: VAR). A 73-year-old prostate cancer patient from Barcelona has become the first patient in the country to receive the fast and efficient treatment.

"The treatment went very well and the patient really noticed the time difference compared with previous treatments," said Dr. Ferran Guedea, head of the radiation oncology department. "It's very important to deliver the dose as quickly as possible, which makes it a better experience for the patient. Fast dose delivery is especially important in organs such as the prostate that are prone to move during treatment."

"We are extremely pleased to be able to offer the latest in radiotherapy to our patients," adds Dr. Guedea. "We believe RapidArc is an enormous leap forward in precise radiotherapy treatments, enabling us to offer a precise and personalized treatment in shorter time." He said early RapidArc treatments would focus on patients with prostate, head & neck and brain tumors, as well as any patients with tumors located close to sensitive organs.

RapidArc delivers a volumetric intensity-modulated radiation therapy (IMRT) treatment in a single or multiple arcs of the treatment machine around the patient and makes it possible to deliver advanced image-guided IMRT two to eight times faster than is possible with conventional IMRT. Since its introduction, Varian has installed more than 410 RapidArc systems in cancer centers globally.  

ICO, a group of three public university-affiliated teaching hospitals, delivers cancer treatments on ten Varian linear accelerators, all equipped with multi-leaf collimators for conformal radiotherapy treatments. In November, RapidArc was installed on one of these treatment machines, a Varian Trilogy® medical linear accelerator, at the Hospitalet de Llobregat in Barcelona, the largest of the three ICO centers serving 1.3 million inhabitants in the Catalonia region.

"We strive to keep the ICO at the leading-edge of cancer treatment and this technology is an important step forward in the battle against cancer," says Dr. Guedea.

Maria Cruz Lizuian, head of medical physics at the ICO, says, "As the main reference center for cancer diagnosis and treatment in the region, we are delighted to begin offering this advanced treatment for patients both in Catalonia and throughout Spain. By offering these fast and efficient treatments, we will be able to offer more patients advanced image-guided and intensity-modulated treatments."

Adolfo Carvajal, the sales director for Varian Iberia, adds, "The ICO group is at the forefront of cutting-edge cancer treatments and we are delighted to be working with them to bring these precise and fast treatments to patients in Spain. More and more hospitals are selecting RapidArc as a way of delivering advanced and precise treatments without putting pressure on waiting lists."    

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,100 people who are located at manufacturing sites in North America, Europe, and China and approximately 79 sales and support offices around the world. For more information, visit http://www.varian.com.

Published papers on this topic:

Kjaer-Kristoffersen F., Ohlhues L., Medin J., Korreman S. RapidArc volumetric modulated therapy planning for prostate cancer patients. Acta Oncology. 2008:48 (2): 227-32

Using Volumetric Modulated Arc Therapy. International Journal of Radiation Oncology*Biology*Physics 1 Sept. 2009: 253-259. ScienceDirect. Web. 26 Oct. 2009

Palma D., Vollans E., James K., Nakano S., Moiseenko V, Shaffer R., McKenzie M., Morris J., Otto K. Volumetric Modulated Arc Therapy for Delivery of Prostate Radiotherapy: Comparison With Intensity-Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy International Journal of Radiation Oncology*Biology*Physics, Volume 72, Issue 4, 15 November 2008, Pages 996-1001

Zhang P., Happersett L., Hunt M., Jackson A., Zelefsky M., Mageras G. Volumetric Modulated Arc Therapy: Planning and Evaluation for Prostate Cancer Cases. International Journal of radiation Oncology*Biology* Physics, [Epub ahead of print]


'/>"/>
SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
2. Use it or Lose it: A New Theory About Preserving Erectile Function After Prostate Surgery
3. Gene Fusion Subtypes in Prostate Carcinoma Have Clinical Implications
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
6. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
7. Study Suggests Soy Protein May Reduce Prostate Cancer Risk
8. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
9. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
10. Prostate Cancer Treatment Centre Receives Funding for Clinical Trials
11. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... , December 2, 2016 ... "In Vitro Diagnostics/IVD Market by Product (Instruments, Reagents, ... Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - ... market is valued at USD 60.22 Billion in ... a CAGR of 5.5% during the forecast period ...
(Date:12/2/2016)... , Dec. 2, 2016 In the ... sources apart from those derived from C. sativa, the ... Universita` di Napoli Federico II , the Universita` ... the first comprehensive, critical, integrated and unified inventory of ... article focuses on the remarkable chemical and structural ...
(Date:12/2/2016)... INDIANAPOLIS , Dec. 2, 2016  Eli Lilly ... its financial guidance for 2017 and provide updated financial ... will also conduct a conference call on that day ... the company,s financial guidance. The conference call ... the general public can access a live webcast of ...
Breaking Medicine Technology:
(Date:12/5/2016)... , ... December 05, 2016 , ... Sabah Shah MD, MBA has joined the ... Group of New York was founded by James M. Maisel, MD and has been providing ... Shah has always followed a legacy of surpassing expectations amongst her peers. Growing up ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... won "Best Surgical Facial Rejuvenation" at the 2016 Anti-Aging & Beauty Awards ... , The Aesthetic & Anti-aging Medicine European Congress (AMEC) brings together ...
(Date:12/4/2016)... York, NY (PRWEB) , ... December 03, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – hosted its first Swirl: A Wine Tasting Event in New York ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... Company in the Dallas area” Tuesday evening at the 26th Annual SMU Cox ... by SMU's Cox School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by the ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges on regular ... to achieve optimal results. This important necessity inspired an inventor from Las Vegas, Nev., ... to ensure that people break or avoid bad techniques of brushing the teeth in ...
Breaking Medicine News(10 mins):